Jazz Pharmaceuticals is teaming up with ImmunoGen on a slate of armed antibodies.
Jazz $JAZZ will pay $175 million — $75 million upfront and $100 million in research support — to claim opt-in rights on a lineup of three antibody-drug conjugates either just in the clinic or planned for human studies. At the top of the list is ImmunoGen’s $IMGN Phase I ADC IMGN779, a CD33-targeted ADC for the treatment of acute myeloid leukemia, and IMGN632, a CD123-targeted ADC for hematological malignancies being teed up for its first Phase I. Another program will be designated for the collaboration later.
It won’t be quick. Jazz’s R&D funding stretches out over 7 years, and the company will be responsible for taking over development on any drug it options. Once an option is in place, ImmunoGen will be in line for unspecified milestones and a range of royalties. ImmunoGen will retain US co-commercialization rights to one or two of the programs, sharing in the costs of getting the drugs through to an approval.
ImmunoGen is using one of its novel indolino-benzodiazepine payloads in ‘779. These drugs work best by latching on to cancer cells and then bombing them with a toxic therapy, bypassing healthy cells.
“This strategic partnership with Jazz significantly advances our goal of accelerating the development of our early-stage novel ADC assets. This deal joins us with a global partner, provides us with substantial funding to support these programs, and preserves the right to co-commercialize one of these assets,” said Mark Enyedy, president and chief executive officer of ImmunoGen.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 25,000+ biopharma pros who read Endpoints News by email every day.Free Subscription